Subscribe
Subscribe

World’s First Thin-Silicon Implantable Chip for High-Precision Haptic Prosthetics

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

While C-Cure had failed an essential phase 3 clinical trial in June last year, the trial identified a subgroup of patients where the drug was effective nonetheless. Based on this fact, C-Cure now receives Fast Track designation from the US drug policy maker.

Biocartis announces its new CEO

Biocartis has revealed its pick for its vacant top function.

Progranulin shortage could cause frontotemporal dementia

Polluted air can generate power

Coffee value can be predicted without tasting

A new unexpected key player in melanoma development identified

Novartis takes license on Celyad’s allogeneic CAR T cells

Yet another phase 2 filgotinib study for Galapagos: cutaneous lupus erythematosus

Galapagos and development partner Gilead set out to explore filgotinib applicability even futher. This time, the molecule's anti-inflammatory capacity will be tested in cutaneous lupus erythematosus.

Kiadis Pharma files EMA marketing authorization for ATIR101™ in blood cancers

Kiadis Pharma asks permission to the EMA to bring its lead product to the market. ATIR101™ protects blood cancer patients receiving a stem cell transplant from vulnerability to infections and disease relapse.

Characterising the profile of metastatic breast cancer for improved treatment

How Europe responds to the demise of the fire salamander

Galapagos raises $338 million gross proceeds in a US public offering

Macrophages to protect you from asthma

It has long been known that exposure to microbes can play a protective role against the subsequent development of asthma. Researchers from GIGA of the University of Liège provide an explanation and propose to use this discovery to set up a strategy of cell therapy to treat asthma in humans. Their discovery is published in Immunity.

CMAST: Bringing ideas from a risky early stage to a viable healthcare solution